Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market

Related Articles

Amazon's Strategic Play in Africa: Leveraging Regulatory Hurdles to Outpace Starlink

3 months ago

What Should Investors Expect from DexCom's Upcoming Q1 Earnings

6 months ago

Cheniere Energy: Geopolitical Tailwinds Outpace Political Headwinds

3 months ago

Why is Tether Gold (XAUt) Expanding to BNB Chain Now

6 months ago

Category

You may also like

Stock News•2 days ago

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Dexcom reported NEJM publication of its CONNECT trial, where G7 CGM users with Type 2 diabetes not on insulin cut A1C by 1.6% from an 8.8% baseline. The data could support broader CGM adoption and pay...

DXCM

Share

Stock News•2 months ago

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Abbott is expanding across diabetes care, oncology diagnostics and heart devices via new launches and acquisitions, creating multiple growth paths.

ABT

Share

Stock News•2 months ago

DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion

DXCM's Q2 results likely show strong G7 15-day adoption and broader reimbursement, with investors watching for continued double-digit revenue growth.

DXCM

Share